Specialized expertise in New Venture Creation and External Innovation, having raised over $160M in venture capital and non-dilutive funding from top-tier institutional and government sources. Proven ability to identify high-impact scientific discoveries and translate them into commercially viable therapeutic platforms across cell and gene therapy, hematology, and novel delivery systems.

 

Jonathan has served as Founder/CEO of:

STRM.BIO, the first gene delivery platform capable of completely bypassing the liver to target long-term hematopoietic stem cells in vivo.

Stellular Bio (formerly Platelet Biogenesis), the first functional human platelets manufactured from iPSCs to treat hematological and oncological diseases.

Jonathan was an Assistant Professor at Brigham & Women’s Hospital and Harvard Medical School, where he established cell culture and microfluidic programs in hematology and oncology, and guided dozens of students toward rewarding careers in medicine and biopharma.

Jonathan earned his Ph.D. in biochemistry and molecular biology from the University of British Columbia and completed his postdoctoral research fellowship in hematology at Harvard Medical School.